Arcturus Therapeutics (NASDAQ:ARCT) Stock Rating Upgraded by Wall Street Zen

Arcturus Therapeutics (NASDAQ:ARCT) was upgraded by equities researchers at Wall Street Zen from a “sell” rating to a “hold” rating in a report released on Saturday, Wall Street Zen reports.

A number of other equities research analysts also recently commented on the company. Cantor Fitzgerald reissued an “overweight” rating on shares of Arcturus Therapeutics in a report on Thursday. BTIG Research lowered their price target on shares of Arcturus Therapeutics from $23.00 to $20.00 and set a “buy” rating on the stock in a research note on Thursday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Arcturus Therapeutics in a report on Friday, July 17th. Citigroup upgraded shares of Arcturus Therapeutics from a “neutral” rating to a “buy” rating and raised their price objective for the company from $8.00 to $20.00 in a research note on Thursday. Finally, Roth Capital reissued a “buy” rating and set a $41.00 price objective on shares of Arcturus Therapeutics in a report on Wednesday, September 2nd. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, three have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Arcturus Therapeutics presently has an average rating of “Moderate Buy” and an average target price of $22.43.

Arcturus Therapeutics Stock Performance

NASDAQ ARCT opened at $13.85 on Friday. The stock has a market capitalization of $393.66 million, a price-to-earnings ratio of -4.18 and a beta of 2.48. The business’s 50 day moving average is $11.21 and its two-hundred day moving average is $8.84. Arcturus Therapeutics has a 12-month low of $5.50 and a 12-month high of $24.17.

Arcturus Therapeutics (NASDAQ:ARCT) last posted its quarterly earnings results on Friday, August 7th. The biotechnology company reported ($0.84) EPS for the quarter, beating the consensus estimate of ($1.00) by $0.16. Arcturus Therapeutics had a negative return on equity of 46.54% and a negative net margin of 317.62%.The business had revenue of $2.96 million during the quarter, compared to analysts’ expectations of $3.11 million. Equities analysts forecast that Arcturus Therapeutics will post -3.48 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the company. Squarepoint Ops LLC boosted its position in shares of Arcturus Therapeutics by 264.8% in the 2nd quarter. Squarepoint Ops LLC now owns 50,253 shares of the biotechnology company’s stock worth $338,000 after buying an additional 36,479 shares in the last quarter. Corient Private Wealth LP purchased a new position in Arcturus Therapeutics during the 2nd quarter valued at about $117,000. Two Sigma Securities LLC acquired a new position in Arcturus Therapeutics during the second quarter worth about $80,000. Hsbc Holdings PLC lifted its holdings in shares of Arcturus Therapeutics by 7.7% in the second quarter. Hsbc Holdings PLC now owns 56,895 shares of the biotechnology company’s stock valued at $394,000 after purchasing an additional 4,070 shares in the last quarter. Finally, Public Employees Retirement System of Ohio purchased a new stake in shares of Arcturus Therapeutics in the second quarter valued at about $229,000. Institutional investors and hedge funds own 94.54% of the company’s stock.

About Arcturus Therapeutics

Arcturus Therapeutics Holdings Inc is a biotechnology company focused on developing medicines based on messenger RNA (mRNA) and other RNA technologies. The company’s platform includes LUNAR, a lipid-mediated delivery system designed to transport nucleic acid medicines into targeted cells, and STARR, a self-amplifying mRNA technology intended to produce therapeutic proteins from relatively small doses of RNA.

Arcturus is developing RNA-based candidates for rare diseases, infectious diseases, and other conditions.